A950130 logo

Access Bio, Inc. Stock Price

KOSDAQ:A950130 Community·₩163.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A950130 Share Price Performance

₩4,660.00
-1480.00 (-24.10%)
₩4,660.00
-1480.00 (-24.10%)
Price ₩4,660.00

A950130 Community Narratives

There are no narratives available yet.

Recent A950130 News & Updates

What Access Bio, Inc.'s (KOSDAQ:950130) 28% Share Price Gain Is Not Telling You

May 22
What Access Bio, Inc.'s (KOSDAQ:950130) 28% Share Price Gain Is Not Telling You

Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 26% But Growth Is Lacking

Jan 06
Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 26% But Growth Is Lacking

Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares

Nov 13
Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares

Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking

Aug 07
Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking

Access Bio, Inc. Key Details

₩74.4b

Revenue

₩58.4b

Cost of Revenue

₩16.0b

Gross Profit

₩37.6b

Other Expenses

-₩21.6b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-615.23
Gross Margin
21.48%
Net Profit Margin
-29.08%
Debt/Equity Ratio
2.4%

Access Bio, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

1 Risk
0 Rewards

About A950130

Founded
2002
Employees
n/a
CEO
Young-Ho Choi
WebsiteView website
accessbio.net

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.5% in the Information Technology sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 15% annually. Market details ›